Publications scientifiques Archive - Centre de recherche du CHU de Québec-Université Laval

article Hasegawa K, Colombo N, Tewari KS, Dubot C, Cáceres MV, Lorusso D, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, de Mendoza MOH, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Jensen E, Toker S, Monk BJ

Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial

JAMA Oncol 2026.

DOI PUBMED

article Millan B, Ghosh S, Basappa NS, Wood L, Bhindi B, Pouliot F, Breau RH, Finelli A, Bansal RK, Graham J, Bjarnason GA, Bosse D, Castonguay V, Winquist E, Heng DYC, Kollmannsberger CK, Lalani AA

Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World Analysis

Clin Genitourin Cancer 24 (4), 2026.

DOI PUBMED

article Curry L, Ghosh S, Arenovich E, Tanguay S, Lalani AA, Heng DYC, Bhindi B, Basappa NS, Graham J, Bjarnason GA, Breau RH, Castonguay V, Soulieres D, Pouliot F, Bosse D, Kollmannsberger CK, Finelli A, Fallah-Rad N, Soleimani M

Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada

J Geriatr Oncol 17 (3), 2026.

DOI PUBMED

article Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…

Can Urol Assoc J 20 (6), 2026.

DOI PUBMED

article Yap TA, Tan DSP, Stathis A, Shapiro GI, Iwasa S, Joerger M, Zhang J, Plummer R, Sawyer MB, Tan DSW, Castonguay V, Gabrail NY, Matsubara N, Wilkinson G, Ludwig M, Schlicker A, Zhou Y, Merz C, Däbritz JHM, Jeffers M, Hreiki J, de Bono JS

Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects

Cancer Discov 15 (10), 2025.

DOI PUBMED

article Lorusso D, Colombo N, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera M, Samouëlian V, Castonguay V, Arkhipov A, Li K, Toker S, Tekin C, Tewari KS, Monk BJ

Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study

Ann Oncol 36 (1), 2025.

DOI PUBMED

article Bou-Nehme Sawaya G, Tanguay S, Wood LA, Kollmannsberger C, Basappa NS, Bansal R, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Dragomir A

Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study

Clin Genitourin Cancer 23 (3), 2025.

DOI PUBMED

article Roberge-Maltais E, Lévesque E, Castonguay V, Marcoux N, Grenier LP, Veilleux M

Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report

Curr Oncol 32 (8), 2025.

DOI PUBMED

article De Vries-Brilland M, Hamilou Z, Ghosh S, Heng DYC, Wood LA, Basappa NS, Kollmannsberger CK, Graham J, Bhindi B, Finelli A, Bjarnason GA, Bosse D, Pouliot F, Castonguay V, Breau RH, Saleh RR, Winquist E, Lalani AA, Soulières D

Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma

Oncologist 30 (9), 2025.

DOI PUBMED

article Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É and Guillemette C

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer

BMC Cancer 25 (1), 2025.

DOI PUBMED

article Sawaya GB, Dragomir A, Wood LA, Kollmannsberger C, Basappa NS, Kapoor A, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Tanguay S

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Eur Urol Oncol 7 (3), 2024.

DOI PUBMED

article Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

ESMO Open 9 (12), 2024.

DOI PUBMED